|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Mucins in neoplasms of pancreas,ampulla of Vater and biliary system显示文摘Tumors of the pancreas,the ampulla of Vater,and the extrahepatic and intrahepatic bile ducts have significant histological similarities due to the common embryonic origin of the pancreatobiliary system.This obviates the need for discovery of biomarkers with diagnostic and prognostic value for these tumors.Mucins,especially MUC-1,-2,-4 and-5AC,are important candidates for developing into such reliable biomarkers.Increased expression of MUC1 occurs in pancreatic ductal adenocarcinomas and is associated with increased degrees of dysplasia in pancreatic intraepithelial neoplasia(Pan IN).Positive expression of MUC2 in intraductal papillary mucinus neoplasms(IPMN) of the intestinal type indicates high potential progression to invasive carcinoma with de novo expression of MUC1,while absence of MUC2 expression in IPMNs of gastric type implies low potential to malignant evolution.De novo MUC4 expression correlates to the severity of dysplasia in Pan IN and is associated with a poor prognosis in patients with pancreatic ductal adenocarcinomas.In biliary intraepithelial neoplasia(Bil IN),increased expression of MUC1 is associated with higher degrees of dysplasia.Intrahepatic cholangiocarcinomas(ICC) are characterized by increased expression of all glycoforms of MUC1.Positive MUC2 expression in intraductal papillary neoplasm of the bile ducts(IPNB) of the intestinal type indicates high malignant potential with de novo expression of MUC1 in the invasive element.Absent MUC2 expression in any degree of Bil IN may prove useful in differentiating them from IPNB.De novo expression of MUC4 is associated with poor prognosis in patients with ICC or carcinoma of the extrahepatic bile ducts(EHBDC).High de novo expression of MUC5 AC is found in all degrees of Bil IN and all types of IPNB and ICC.The MUC5 AC is useful in the detection of neoplastic lesions of the bile duct at an early stage.Increased expression of mucin MUC1 in carcinoma of the ampulla of Vater associated with unfavorable behavior of the tumor,such as lymph node metastasis,infiltration of the pancreas and duodenum,advanced TNM classification and worse prognosis.Patients withintra-ampullary papillary-tubular neoplasm(IAPN) of the pancreatobiliary immunophenotype did not show MUC2,while those of the intestinal immunophenotype are MUC2 positive.The expression of MUC4 is associated with poor prognosis in patients with carcinoma of the ampulla of Vater favoring metastasis and making them resistant to apoptosis.Moreover,it appears that MUC4 positivity correlates with recurrence of the tumor.Expression of MUC5 AC is associated with the invasive potential of the tumor. | Dimitrios Moschovis Giorgos Bamias Ioanna Delladetsima | 2016 | World Journal of Gastrointestinal Oncology2016，8，10： | 4 |
| 2 | Markers of bacterial translocation in end-stage liver disease显示文摘Bacterial translocation(BT) refers to the passage of viable bacteria or bacterial products from the intestinal lumen, through the intestinal epithelium, into the systemic circulation and extraintestinal locations. The three principal mechanisms that are thought to be involved in BT include bacterial overgrowth, disruption of the gut mucosal barrier and an impaired host defence.BT is commonly observed in liver cirrhosis and has been shown to play an important role in the pathogenesis of the complications of end stage liver disease, including infections as well as hepatic encephalopathy and hepatorenal syndrome. Due to the importance of BT in the natural history of cirrhosis, there is intense interest for the discovery of biomarkers of BT. To date, several such candidates have been proposed, which include bacterial DNA, soluble CD14, lipopolysaccharides endotoxin, lipopolysaccharide-binding protein, calprotectin and procalcitonin. Studies on the association of these markers with BT have demonstrated not only promising data but, oftentimes, contradictory results. As a consequence, currently, there is no optimal marker that may be used in clinical practice as a surrogate for the presence of BT. | Ioannis Koutsounas Garyfallia Kaltsa Spyros I Siakavellas Giorgos Bamias | 2015 | World Journal of Hepatology2015，7，20： | 2 |
| 3 | Fecal calprotectin measurement is a marker of shortterm clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease显示文摘AIM To evaluate the utility of fecal calprotectin(FC) in predicting relapse and endoscopic activity during follow-up in an inflammatory bowel disease(IBD) cohort.METHODS All FC measurements that were obtained during a 3-year period from patients with inflammatory bowel disease in clinical remission were identified. Data regarding the short-term(6 mo) course of the disease were extracted from the medical files. Exclusion criteria were defined as:(1) An established flare of the disease at the time of FC measurement,(2) Loss to follow up within 6 mo from baseline FC measurement, and,(3) Insufficient data on file. Statistical analysis was performed to evaluate whether baseline FC measurement could predict the short term clinical relapse and/or the presence of mucosal healing.RESULTS We included 149 [Crohn's disease(CD) = 113, Ulcerative colitis(UC) = 36, male = 77] IBD patients in our study. Within the determined 6-month period post-FC measurement, 47(31.5%) had a disease flare. Among 76 patients who underwent endoscopy, 39(51.3%) had mucosal healing. Baseline FC concentrations were significantly higher in those who had clinical relapse compared to those who remained in remission during follow up(481.0 μg/g, 286.0-600.0 vs 89.0, 36.0-180.8, P < 0.001). The significant predictive value of baseline median with IQR FC for clinical relapse was confirmed by multivariate Cox analysis [HR for 100μg/g: 1.75(95%CI: 1.28-2.39), P = 0.001]. Furthermore, lower FC baseline values significantly correlated to the presence of mucosal healing in endoscopy(69.0 μg/g, 30.0-128.0 vs 481.0, 278.0-600.0, in those with mucosal inflammation, median with IQR, P < 0.001). We were able to extract cut-off values for FC concentration with a high sensitivity and specificity for predicting clinical relapse(261 μg/g with AUC = 0.901, sensitivity 87.2%, specificity 85.3%, P < 0.001) or mucosal healing(174 μg/g with AUC = 0.956, sensitivity 91.9%, specificity 87.2%, P < 0.001). FC was better than CRP in predicting either outcome; nevertheless, having a pathological CRP(> 5 mg/L) in addition to the cutoffs for FC, significantly enhanced the specificity for predicting clinical relapse(95.1% from 85.3%) or endoscopic activity(100% from 87.2%). CONCLUSION Serial FC measurements may be useful in monitoring IBD patients in remission, as FC appears to be a reliable predictor of short-term relapse and endoscopic activity. | Athanasios Kostas Spyros I Siakavellas Charalambos Kosmidis Anna Takou Joanna Nikou Georgios Maropoulos John Vlachogiannakos George V Papatheodoridis Ioannis Papaconstantinou Giorgos Bamias | 2017 | World Journal of Gastroenterology2017，23，41： | 2 |
| 4 | Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis显示文摘Ulcerative colitis(UC) is an immune-mediated, chronic inflammatory disease of the large intestine. Its course is characterized by flares of acute inflammation and periods of low-grade chronic inflammatory activity or remission. Monoclonal antibodies against tumor necrosis factor(anti-TNF) are part of the therapeutic armamentarium and are used in cases of moderate to severe UC that is refractory to conventional treatment with corticosteroids and/or immunosuppressants. Therapeutic response to these agents is not uniform and a large percentage of patients either fail to improve(primary non-response) or lose response after a period of improvement(secondary non-response/loss of response). In addition, the use of anti-TNF agents has been related to uncommon but potentially serious adverse effects that preclude their administration or lead to their discontinuation. Finally, use of these medications is associated with a considerable cost for the health system. The identification of parameters thatmay predict response to anti-TNF drugs in UC would help to better select for patients with a high probability to respond and minimize risk and costs for those who will not respond. Analysis of the major clinical trials and the accumulated experience with the use of anti-TNF drugs in UC has resulted to the report of such prognostic factors. Included are clinical and epidemiological characteristics, laboratory markers, endoscopic indicators and molecular(immunological/genetic) signatures. Such predictive parameters of long-term outcomes may either be present at the commencement of treatment or determined during the early period of therapy. Validation of these prognostic markers in large cohorts of patients with variable characteristics will facilitate their introduction into clinical practice and the best selection of UC patients who will benefit from anti-TNF therapy. | Evanthia Zampeli Michalis Gizis Spyros I Siakavellas Giorgos Bamias | 2014 | World Journal of Gastrointestinal Pathophysiology2014，5，3： | 2 |
| 5 | High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis显示文摘 | Giorgos Bamias Garyfallia Kaltsa Spyros I. Siakavellas Kostis Papaxoinis Evanthia Zampeli Spyros Michopoulos Irene Zouboulis-Vafiadis Spiros D. Ladas | 2010 | Clinical Immunology2010，，2： | 2 |
| 6 | Probiotics in inflammatory bowel disease: Pathophysiological background and clinical applications显示文摘Ulcerative colitis and Crohn's disease, collectively termed the inflammatory bowel diseases(IBD), are chronic inflammatory disorders of the gastrointestinal tract. A 'dysbiotic' relationship between the commensal gut flora and the intestinal mucosa-associated immune system has been at the core of the pathogenesis of these conditions. Probiotics are 'good bacteria' with the ability to benefit the health of the host and their therapeutic application has been studied in IBD. The theoretical basis for such utilization relies upon the ability of probiotic microorganisms to interfere with the dysregulated homeostasis that takes place in IBD and restore the immune-bacterial interaction at the intestinal mucosa. Proposed mechanisms of action include the reconstitution of altered flora composition, enhancement of the integrity of the epithelial barrier, promotion of tolerogenic action by dendritic cells, strengthening of the defensive mechanisms of the innate immunity, and the suppression of pro-inflammatory adaptive immune responses. Despite this abundance of supporting experimental evidence, clinical application of probiotics in IBD has been disappointing. Possible explanations for such discrepancy include the great diversity of microorganisms that fall under the definition of probiotics, the lack of standardization of dosages and administration schemes, the heterogeneity between clinical trials, and the inclusion in the treatment arms of patients with a large variety of clinical phenotypes. Addressing these important issues will be critical for the optimal usage of probiotic-based therapies for patients with IBD. | Cristiano Pagnini Gianfranco Delle Fave Giorgos Bamias | 2013 | World Journal of Immunology2013，3，3： | 2 |
| 7 | Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with beta-catenin levels and outcome in patients with epithelial ovarian cancer显示文摘 | Bamias A Yh Z Weinberger PM | 2006 | Ann Oncol2006，17，12： | 1 |
| 8 | Differential expression of the TL1A/DcR3 system of TNF/TNFR-like proteins in large vs. small intestinal Crohn’s disease显示文摘 | Giorgos Bamias Garyfallia Kaltsa Spyros I. Siakavellas Michalis Gizis George Margantinis Evanthia Zampeli Irene Vafiadis-Zoumboulis Spyros Michopoulos George L. Daikos Spiros D. Ladas | 2011 | Digestive and Liver Disease2011，，1： | 1 |
| 9 | Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor -kappa B ligand (RANKL)/ osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton显示文摘 | Mountzios G Dimopoulos MA Bamias A | 2007 | Acta Oncol2007，46，2： | 1 |
| 10 | Role of the IL-23/IL-17 axis in Crohn's disease 显示文摘 | Siakavellas SI Bamias G | 2012 | Discov Med2012，14，77： | 1 |
| 11 | Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor- kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton 显示文摘 | Mountazios G Dimopoulos MA Bamias A | 2007 | Acta Oncol2007，46，2： | 1 |
| 12 | Thalidomide in cancer medicine显示文摘 | Eleutherakis - Papaiakovou V Bamias A Dimopoulos MA | 2004 | Ann Oncol2004，15，8： | 1 |
| 13 | Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer显示文摘 | Psyrri A Kassar M Yu Z Bamias A Weinberger P M Markakis S | 2005 | Clin Cancer Res2005，11，： | 1 |
| 14 | Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE) 显示文摘 | Raaschou-Nielsen 0 Andersen ZJ Beelen R Samoli E Stafoggia M Weinmayr G Hoffmann B Fischer P Nieuwenhuijsen MJ Brunekreef B Xun WW Katsouyanni K Dimakopoulou K Sommar J Forsberg B Modig L Oudin A Oftedal B Schwarze PE Nafstad p De Faire U Pedersen NL Ostenson CG Fratiglioni L Penell J Korek M Pershagen G Eriksen KT Serensen M Tjenneland A Ellermann T Eeftens M Peeters PH Meliefste K Wang M Bueno-de-Mesquita B Key TJ de Hoogh K Concin H Nagel G Yilier A Grioni S Krogh y Tsai MY Ricceri F Sacerdote C Galassi C Migliore E Ranzi A Cesaroni G Badaloni C Forastiere F Tamayo I Amiano P Dorronsoro M Trichopoulou A Bamia C Yineis p Hoek G | 2013 | Lancet Oncol2013，14，9： | 1 |
| 15 | Pulmonary toxic- ity from novel antineoplastic agents 显示文摘 | Dimopoulou I Bamias A Lyberopoulos P | 2006 | Ann Oncol2006，17，： | 1 |
| 16 | The prognostic significance of theexpression of p53, bcl-2, e-erb B-2 and eathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy 显示文摘 | Protopapas A Diakomanolis E Bamias A | 2004 | Eur J Gyneeol Oncel2004，25，2： | 1 |
| 17 | Circulating levels of TNF - like cytokine 1A ( TL1A ) and its decoy receptor 3 ( DcR3 ) in rheumatoid arthritis 显示文摘 | Bamias G Siakavellas SI Stamatelopoulos KS | 2008 | Clin Immunol2008，129，2： | 1 |
| 18 | Circulating levels of TNF-like cytokine 1A (TLI A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis显示文摘 | Bamias G Siakavellas SI Stamatelopoulos KS | 2008 | Clin Immunol2008，129，2： | 1 |
| 19 | Dimopoulos Angiogenesis in human cancer: implications in cancer therapy 显示文摘 | Aristotle Bamias and Meletios A | 2003 | Eur J Int Med2003，14，： | 1 |
| 20 | Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease 显示文摘 | Bamias G Martin C Marini M | 2003 | J Immunol2003，171，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员